•   George Lundberg, MD

    Research paper from the Journal of Clinical Oncology curated by Editor in Chief George Lundberg, MD, who notes: 

    Eighty percent of ovarian cancers are first diagnosed after they have already spread. In the clinical trial discussed in this paper, a combination of two checkpoint inhibitor immunotherapy drugs showed only modest benefit in advanced ovarian cancer.

    Go to full paper published in the Journal of Clinical Oncology.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Research paper from The New England Journal of Medicine curated by Editor in Chief George Lundberg, MD, who notes: 

    These clinical trials results suggest that the drug niraparib is superior to platinum-based chemotherapy for people with newly diagnosed advanced ovarian cancer.

    Go to full paper published in The New England Journal of Medicine.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Article from Cancer Network curated by Editor in Chief George Lundberg, MD, who notes: 

    In a phase III clinical trial, a triple-drug therapy nearly triples overall survival for patients with colorectal cancer.

    Go to full article published by Cancer Network.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Research paper from The Lancet curated by Editor in Chief George Lundberg, MD, who notes: 

    A drug called Cyramza improves progession-free survival (PFS) but not overall survival (OS) of patients with advanced bladder cancer in a phase lll clinical trial.

    Go to full paper published in The Lancet.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Article from Medscape curated by Editor in Chief George Lundberg, MD, who notes: 

    Drugs known as PARP inhibitors can improve progression-free survival (PFS) in many patients with advanced ovarian cancers.

    Go to full article published by Medscape.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Research paper from Annals of Surgery curated by Editor in Chief George Lundberg, MD, who notes: 

    This meta-analysis found that minimally invasive surgery tops open esophagectomy for esophageal cancer.

    Go to full paper published in Annals of Surgery.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Research paper from the Journal of Clinical Oncology curated by Editor in Chief George Lundberg, MD, who notes: 

    Niraparib substantially improves TWIST (time without symptoms or toxicity) over no treatment in recurrent epithelial ovarian cancers, even moreso if positive for gBRCAmu.

    Go to full paper published in the Journal of Clinical Oncology.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes: 

    In a clinical trial, a new combination therapy conferred better response rates, progression-free survival, and overall survival than standard sorafinib for unresectable hepatocellular carcinoma.

    Go to full article published by The ASCO Post.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Research paper from Annals of Surgery curated by Editor in Chief George Lundberg, MD, who notes: 

    This clinical trial found no difference in tumor-free margins from standard versus artery-first surgical techniques for the resection of pancreatic head adenocarcinoma via pancreatoduodenectomy.

    Go to full paper published in Annals of Surgery.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Research paper from The Lancet curated by Editor in Chief George Lundberg, MD, who notes: 

    In this clinical trial, nivolumab was somewhat superior to chemotherapy for advanced esophageal carcinoma.

    Go to full paper published in The Lancet.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.